Bellus Health gets global license to Neomed Institute's preclinical cough candidate; deal terminated
Bellus Health Inc. received exclusive worldwide rights to develop and commercialize the Neomed Institute's chronic cough candidate NEO5937, which Bellus has renamed BLU5937.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.